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Mutations in the leucine-rich repeat kinase 2 gene (LRRK2) are associated with familial and sporadic Parkinson’s disease (PD).
LRRK2 is a complex protein that consists of multiple domains, including predicted C-terminal WD40 repeats. In this study, we
analyzed functional and molecular features conferred by the WD40 domain. Electron microscopic analysis of the purified
LRRK2 C-terminal domain revealed doughnut-shaped particles, providing experimental evidence for its WD40 fold. We demon-
strate that LRRK2 WD40 binds and sequesters synaptic vesicles via interaction with vesicle-associated proteins. In fact, a do-
main-based pulldown approach combined with mass spectrometric analysis identified LRRK2 as being part of a highly specific
protein network involved in synaptic vesicle trafficking. In addition, we found that a C-terminal sequence variant associated
with an increased risk of developing PD, G2385R, correlates with a reduced binding affinity of LRRK2 WD40 to synaptic vesicles.
Our data demonstrate a critical role of the WD40 domain within LRRK2 function.
Parkinson’s disease (PD) is the second most common age-re-lated neurodegenerative disease and is clinically characterized
by movement impairments, bradykinesia, rigidity, and resting
tremor and pathologically by the progressive loss of dopaminergic
neurons in the substantia nigra and the formation of Lewy bodies
(1, 2). Although the majority of cases are sporadic, mutations in
the leucine-rich repeat kinase 2 (LRRK2) gene (PARK8; Online
Mendelian Inheritance in Man [OMIM] accession number
609007) had been unequivocally linked to late-onset autosomal
dominant PD. LRRK2 mutations account for up to 13% of famil-
ial PD cases compatible with dominant inheritance and are also
found in 1 to 2% of sporadic PD patients (62–64). LRRK2 is a
complex 286-kDa protein that consists of multiple domains, in-
cluding (in order, from the amino to carboxyl terminus) arma-
dillo, ankyrin, and the namesake leucine-rich repeats (LRRs), fol-
lowed by an ROC (Ras of complex proteins) GTPase domain, a
COR (C-terminal of ROC) dimerization domain, a kinase do-
main, and a predicted C-terminal WD40 repeat domain (4–6).
Several single-nucleotide alterations have been identified in
LRRK2, but only five missense mutations within the ROC, COR,
and kinase domains clearly segregate with PD in large family stud-
ies (7, 8). It has recently been shown that the WD40 domain is
required to stabilize the LRRK2 dimer and to execute LRRK2-
associated kinase activity as well as neurotoxicity (9, 10), but the
role of this domain within LRRK2 physiological and pathological
function has not yet been completely defined. The beta-propeller-
forming WD40 domains are among the 10 most abundant do-
main types across eukaryotic proteomes (11) and constitute plat-
forms where multiprotein complexes assemble reversibly (12).
Here, we systematically analyzed the protein-protein interactions
conferred by the LRRK2 WD40 domain. The nature of the LRRK2
WD40 interactors and the finding that the LRRK2 WD40 domain
is able to bind to synaptic vesicles (SV) contribute to accumulating
evidence suggesting that LRRK2 serves as a scaffold protein con-
necting vesicle trafficking and cytoskeleton (13). Strong genetic
association indicates that the substitution of arginine for glycine
2385 (G2385R) within the LRRK2 WD40 domain is a pathologi-
cally relevant variant (14). This variant is considered a common
risk factor for sporadic PD in Chinese Han and Korean ethnicity,
but its functional impact is largely unknown (15, 16). We demon-
strate that the G2385R variant alters LRRK2 WD40 binding to
synaptic vesicles. Altogether, these data suggest that the LRRK2
WD40 domain is a determinant for LRRK2 physiological and
pathological activities.
MATERIALS AND METHODS
Cell cultures. Cortical neuron cultures were prepared from embryonic
day 15.5 to 16.5 mouse cortexes (C57BL/6). Medium-density (150 to 200
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cells/mm2) neuron cultures were plated and grown in Neurobasal culture
medium supplemented with 2% B27 and 0.1% gentamicin on 24-well
plastic tissue culture plates (Iwaki; Bibby Sterilin, Staffordshire, United
Kingdom). In such cultures glial growth is reduced to less than 0.5% of the
nearly pure neuronal population (17). HEK293T (ATCC CRL-11268)
cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with 10% fetal bovine serum (FBS) and 1% penicillin-strepto-
mycin mix according to standard protocols. All media were purchased
from Life Technologies.
Plasmids and transfection. Human LRRK2 LRR (amino acids [aa]
921 to 1356), LRRK2 WD40 (aa 2124 to 2527), full-length RACK1, and
full-length human LRRK2 were subcloned into pDEST-15 (N-terminal
glutathione S-transferase [GST] tag) and/or pDEST-733 (N-terminal red
fluorescent protein [RFP] tag) using the Gateway system (Life Technolo-
gies) as described previously (18). The LRRK2 WD40 G2385R variant as
well as FLAG- and RFP-tagged LRRK2 consisting of residues 1 to 2141
(hereinafter termed LRRK2 1–2141) were generated by site-directed mu-
tagenesis using a QuikChange mutagenesis kit (Stratagene). Cloning of
pGEX-RACK1 and full-length FLAG-LRRK2 was described previously
(18–20). LRRK2 WD40 consisting of aa 2148 to 2527 with six copies of a
His tag (6His) was cloned into pETM11. pGFP (where GFP is green
fluorescent protein) and pDsRed2-1 were purchased from Clontech lab-
oratories. Neurons were transfected at 10 days of in vitro culture (DIV10)
with GFP and RFP-tagged constructs or DsRed in a 1:3 ratio by calcium
phosphate precipitation as previously described (21) and processed when
indicated in the text.
Purification of GST- and His-tagged proteins. GST fusion proteins
containing single LRRK2 domains and GST-RACK1 were expressed in the
Escherichia coli BL21 strain (Life Technologies), purified as described ear-
lier (22). The purification procedure for the N-terminal 6His-tagged
LRRK2 WD40 construct (LRRK2 2148-end), used for electron micros-
copy (EM) analysis, has been adapted to that used for the GST fusion
proteins. Briefly, for expression, E. coli cells were grown in terrific broth
(TB) medium with 0.1 mM isopropyl--D-thiogalactopyranoside (IPTG)
induction overnight at 18°C. Cells were lysed in 20 mM Tris, pH 7.5, 150
mM NaCl, 2 mM beta-mercaptoethanol (BME), 0.7% Sarkosyl, and 2%
Triton X-100 by sonication. The lysate was loaded onto a nickel column,
and the column was then washed with 20 column volumes each of lysis
buffer and high-salt buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 350 mM
KCl, 5 mM MgCl2, 1 mM ATP). The His-tagged protein was finally eluted
with lysis buffer containing 150 mM imidazole. The protein was then
dialyzed overnight against 20 mM Tris, pH 7.5, 150 mM NaCl, and 5 mM
dithiothreitol (DTT).
Subcellular fractionation and synaptic vesicle binding assay. Sub-
cellular fractionation of rat forebrain tissue was carried out as previously
described in the presence of protease inhibitors (23). Briefly, the freshly
dissected cerebral cortex was homogenized with a glass-Teflon homoge-
nizer in ice-cold buffered sucrose (0.32 M sucrose, 5 mM HEPES, pH 7.4)
(homogenate) and centrifuged at 800  g for 10 min. The nuclear pellet
was discarded, and the postnuclear supernatant (containing cell mem-
brane, cytosol, and organelles; S1 fraction) was centrifuged at 9,200  g
for 15 min to give a supernatant fraction (containing cytosol and micro-
somes; S2 fraction) and a crude mitochondrial pellet (containing mito-
chondria and synaptosomes; P2 fraction). The P2 fraction was subjected
to osmotic lysis by homogenization in 10 volumes of ice-cold water and
centrifuged at 25,000 g for 20 min to yield a lysate pellet (LP1) enriched
in presynaptic plasma membranes and a lysate supernatant (LS1). The
LS1 fraction was further centrifuged at 16,500  g for 2 h to yield a
synaptosolic fraction (LS2) and a crude SV pellet (LP2) containing syn-
aptic vesicles and small presynaptic plasma membranes. The LP2 fraction
was further fractionated by centrifugation through a continuous sucrose
gradient and chromatography through a controlled-pore glass column to
yield highly purified SV (untreated SV [US]) and a column flowthrough
(FT). When required, purified SV were partially depleted of endogenous
proteins by dilution in 0.2 M NaCl (salt-treated SV, SSV). SV were cen-
trifuged at 200,000  g for 2 h after 2 h of incubation at 0°C. After cen-
trifugation, SV were resuspended in 0.3 M glycine, 5 mM HEPES-NaOH,
pH 7.4, at a protein concentration of 1.5 to 2 mg/ml. The binding of GST
fusion proteins to SV was carried out using a high-speed sedimentation
assay (24). Briefly, SV (5 to 10 g of total protein) were incubated for 1 h
at 0°C with increasing amounts of a GST fusion protein in a buffer con-
taining 220 mM glycine, 30 mM NaCl, 5 mM Tris-HCl, 4 mM HEPES (pH
7.4), 0.22 mM NaN3, and 100 g/ml of bovine serum albumin (BSA).
After the incubation, GST fusion protein which bound to SV was sepa-
rated by high-speed centrifugation (400,000 g for 30 min). Aliquots of
the resuspended pellets were subjected to SDS-PAGE and subsequent
Western blotting with GST-specific antibodies. The amount of GST pro-
tein was determined as a function of optical density in comparison to
known amounts of fusion proteins. The recovery of SV, used to correct the
amounts of fusion protein bound to SV, was determined by Western
blotting with antisynaptophysin antibodies. FLAG-LRRK2 was purified
via affinity chromatography using FLAG-M2 agarose beads (Sigma-Al-
drich) from HEK293T cells transfected by lipofection using Lipo-
fectamine 2000 (Life Technologies) according to the manufacturer’s in-
structions. The binding of FLAG-LRRK2 to SV was performed as
described above with minor modifications: only one concentration of
fusion protein (50 nM) was assayed, and FLAG-LRRK2 yield was evalu-
ated via Western blotting with FLAG-specific antibodies.
Pulldown, immunoprecipitation, and antibodies. For pulldowns, 5
g of each GST fusion protein was loaded onto glutathione-Sepharose
resin (GE Healthcare) and coincubated with adult mouse brain lysate or
the LS1 fraction (1 mg of total protein). In immunoprecipitation assays,
10 g of 1E11 anti-LRRK2 antibody was incubated with 1 mg of protein
lysate and loaded onto protein G-Sepharose resin (GE Healthcare). In
both procedures, resins were extensively washed in Tris-EDTA buffer (10
mM Tris-HCl, pH 8.0, 1 mM EDTA, 150 mM NaCl, 0.2% Triton X-100),
followed by final elution of the samples with Laemmli buffer. For protein
identification by Western blotting, samples were loaded onto 4 to 12%
NuPAGE gels (Invitrogen); the proteins were transferred onto a nitrocel-
lulose membrane (Sigma-Aldrich) at 80 V for 120 min at 4°C. The pri-
mary antibodies were applied overnight in blocking buffer (20 mM Tris,
pH 7.4, 150 mM NaCl, 0.1% Tween 20, and 5% nonfat dry milk); primary
antibodies (source in parentheses) included rat monoclonal anti-LRRK2
1E11 at 1:1,000 (that recognizes an epitope within the LRRK2 kinase do-
main [25]), mouse anti-synapsin I at 1:1,000 (Synaptic System), mouse
anti-SNAP-25 at 1:1,000 (Chemicon), rabbit anti-MAP2 at 1:1,000,
mouse anti-MAP6 at 1:1,000, rabbit anti-N-ethylmaleimide-sensitive fac-
tor (anti-NSF; 1:1,000 [Cell Signaling]), mouse anti-FLAG at 1:2,000,
mouse anti-Rac1 at 1:1,000, mouse anti--actin at 1:1,000 mouse anti-
syntaxin 1A at 1:1,000, mouse anti-Rab3A at 1:1,000, and mouse anti--
tubulin at 1:1,000 (Sigma-Aldrich). Secondary antibodies (horseradish
peroxidase [HRP]-conjugated anti-mouse, anti-rabbit, or anti-rat anti-
bodies; Jackson ImmunoResearch) were used in a ratio of 1:8,000. The
signal was detected using an enhanced chemiluminescence (ECL) detec-
tion system (GE Healthcare). Films (Hyperfilm ECL; GE Healthcare) were
digitalized using a GS-800 densitometer (Bio-Rad) calibrated according
to the manufacturer’s instructions, and protein abundance was estimated
as a function of the optical density of a specific band quantified by ImageJ
software (NIH).
MS/MS identification. Liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) analysis was performed on an Ultimate 3000 Nano
high-performance liquid chromatography (HPLC) system (Dionex) cou-
pled to a linear trap quadrupole (LTQ) OrbitrapXL mass spectrometer
(Thermo Fisher Scientific) by a nanospray ion source. Tryptic peptide
mixtures were automatically injected and loaded at a flow rate of 30 l/
min in 95% buffer C (0.5% trifluoroacetic acid in HPLC-grade water) and
5% buffer B (98% acetonitrile and 0.1% formic acid in HPLC-grade wa-
ter) onto a nanotrap column (100-m interior diameter [i.d.] by 2 cm;
Acclaim PepMap100 C18 column, 5-m particle diameter, 100-Å pore
size [Dionex]). After 5 min, peptides were eluted and separated on the
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analytical column (75-m i.d. by 15 cm; Acclaim PepMap100 C18 col-
umn, 3-m particle diameter, 100-Å pore size [Dionex]) by a linear gra-
dient from 5% to 40% of buffer B in buffer A (2% acetonitrile and 0.1%
formic acid in HPLC grade water) at a flow rate of 300 nl/min over 90 min.
Remaining peptides were eluted by a short gradient from 40% to 100%
buffer B in 5 min. The eluted peptides were analyzed by the LTQ Or-
bitrapXL mass spectrometer. From the high-resolution mass spectrome-
try prescan with a mass range of 300 to 1,500, the 10 most intense peptide
ions were selected for fragment analysis in the linear ion trap if they ex-
ceeded an intensity of at least 200 counts and if they were at least doubly
charged. The normalized collision energy for collision-induced dissocia-
tion was set to a value of 35, and the resulting fragments were detected
with normal resolution in the linear ion trap. The lock mass option was
activated; the background signal with a mass of 445.12002 was used as lock
mass (26). Every ion selected for fragmentation was excluded for 30 s by
dynamic exclusion. The acquired spectra were processed and analyzed by
using Mascot Daemon (version 2.4.0) in combination with ExtractMSN
(Thermo-Fisher) with the following settings: cysteine carbamidomethy-
lation as a fixed modification and methionine oxidation and asparagine/
glutamine deamidation as variables with a maximum of three modifica-
tions per peptide allowed. Mass tolerances for parent and fragment
peptides were set to 10 ppm and 1.00 Da, respectively. The database used
consisted of a combined set of mouse and E. coli subsets of the Swiss-Prot
database (UniProt release 2012_7, published on 11 July 2012; 20,847 en-
tries plus decoy) with spiked-in bait proteins (human LRRK2 and GST of
Schistosoma japonicum). Reversed sequences generated by Scaffold were
used as a decoy. Mascot result files were analyzed by the Scaffold software
(version 4.1.1) (Proteome Software, Inc., Portland, OR) to validate MS/
MS-based peptide and protein identifications. Peptide identifications
were accepted if they could be established at greater than 90% probability
as specified by the Peptide Prophet algorithm (27). Protein identifications
were accepted if they could be established at greater than 95% probability
and contained at least two identified unique peptides. Protein probabili-
ties were assigned by the Protein Prophet algorithm (28). Proteins that
contained similar peptides and could not be differentiated based on
MS/MS analysis alone were grouped to satisfy the principles of parsimony.
The final data sets describing the LRRK2 interactome were generated
based on at least four independent experiments for each bait (LRRK2
WD40, LRRK2 LRR, and GST control). Proteins were considered specific
LRRK2 WD40 interactors if they were found in at least two independent
pulldown experiments and if they were, based on spectral counting, at
least 2-fold enriched in the LRRK2 WD40 pulldown set compared to the
GST control set. Typical contaminants, including E. coli proteins, ribo-
somal proteins, and keratins, were excluded.
Exoendocytotic assay, immunocytochemistry, and quantification.
The endocytosis assay to monitor SV recycling was performed as de-
scribed previously with minor modifications (13, 29) in neurons trans-
fected at DIV12 with RFP-WD40 or RFP-RACK1 or DsRed plus GFP to
visualize cellular processes. Briefly, rabbit polyclonal antibodies directed
against the intravesicular domain of synaptotagmin 1 (Synaptic System)
were diluted 1:400 in Tyrode solution (124 mM NaCl, 5 mM KCl, 5 mM
CaCl2, 1 mM MgCl2, 30 mM glucose, 25 mM HEPES, pH 7.4) and applied
for 5 min at room temperature (RT) on living cultures. After extensive
washing with Tyrode solution, neurons were fixed in 4% paraformalde-
hyde and 4% sucrose at room temperature. Where indicated in the figure
legends, rat anti-FLAG (1:100; kindly provided by E. Kremmer, Institute
of Molecular Immunology, Helmholtz Zentrum München), rabbit anti-
SV2A (1:400; Synaptic System), or mouse anti-SNAP-25 (1:1,000; Sigma-
Aldrich) antibody was applied in GDB buffer (30 mM phosphate buffer,
pH 7.4, containing 0.2% gelatin, 0.5% Triton X-100, and 0.8 M NaCl)
overnight at 4°C. Cy5-coupled secondary antibodies and 4=,6=-di-
amidino-2-phenylindole (DAPI; Life Technologies) were diluted 1:1,000
in GDB buffer and applied for 1 h. Transfected neurons were randomly
chosen in at least four independent experiments for each condition. The
fluorescence images were acquired using an LSM Zeiss 510 confocal mi-
croscope with a Zeiss 63 objective (Karl Zeiss, Jena, Germany) at a
resolution of 1 pixel equal to 0.098 m. Image analysis was performed
using ImageJ (NIH). To quantify synaptotagmin- or SV2A-positive clus-
ters, GFP-positive processes were manually tracked, and the number of
positive clusters in the region of interest was automatically counted. To
evaluate neuron morphology, neurites were randomly selected and man-
ually traced, and length and number of processes were automatically de-
termined and logged into Microsoft Excel as described previously (30).
Electron microscopy. Purified GST- or 6His-tagged fusion proteins
were adsorbed onto carbon-coated grids that were glow discharged in air
before the application of 5 l of protein solution. Excess protein solution
was blotted off after 2 min. The adsorbed molecules were negatively
stained for 30 s using 5 l of stain solution as indicated in the figure
legends. Micrographs were recorded on Kodak SO-163 image film (Sigma-
Aldrich) using JEOL JEM 2010 and JEOL JEM 100CX electron micro-
scopes operated at 120 and 100 kV, respectively, at defocus values of 600 to
900 nm. Suitable micrographs were selected by optical diffraction and
digitized using a Flextight Precision II (Hasselblad) scanner, resulting in
pixel sizes of 1.59 or 1.28 Å at the specimen level. Particles were selected
and extracted using EMAN1 (31) and classified using IMAGIC, version
5.0 (Image Science Software).
Homology modeling. Modeling templates were identified in the Pro-
tein Data Bank (PDB) (32, 33) using the profile-profile alignment pro-
gram Phyre2 (3). The initial homology model was built based on the
WD40 domain structure of RACK1 from Arabidopsis thaliana (PDB code
3DM0) (34). The model structure was further refined using the YASARA
energy minimization server to increase the model accuracy (35). The
quality of the final structure model was validated using PROCHECK (36).
PyMOL was used for visualization of the final model.
Statistical analysis. All data are expressed as means standard error
of the means (SE). Data were analyzed with an unpaired Student’s t test
(two classes) or by analysis of variance (ANOVA) followed by Tukey’s post
hoc test (more than two classes). The indication of the number of exper-
iments (n) and level of significance (P) are given throughout the text.
Database accession number. The interactome data set has been sub-
mitted to the IntAct database under accession number IM-20537 (http:
//www.ebi.ac.uk/intact/search/do/search?searchStringimex:IM-20537).
RESULTS
WD40 links LRRK2 to presynaptic proteins. Previous findings,
including our own work, suggest that LRRK2 regulates trafficking
of synaptic vesicles (SV) (13, 37, 38). Here, we investigated the
interaction between LRRK2 and SV at the molecular level. For this
purpose, we first tested the subcellular distribution of LRRK2.
Subcellular fractionation of mouse brain lysate revealed cosedi-
mentation of LRRK2 with synapsin I and synaptophysin in a bio-
chemically defined fraction enriched in SV (Fig. 1A, lane US).
Interestingly, mild salt treatment, reported to partially remove
associated proteins such as synapsin I from SV (23), did not re-
duce the amount of LRRK2 or synaptophysin found in the SV
fraction (Fig. 1A, lane SSV). Next, we incubated full-length FLAG-
LRRK2 at a nanomolar concentration with purified SV and tested
the extent of binding in a high-speed sedimentation assay (24).
Western blot analysis using a FLAG-specific antibody revealed
that recombinant LRRK2 associates to native SV. Interestingly,
LRRK2 showed a binding affinity similar to that of SSV (Fig. 1B
and C). In the same SV population we described a strong reduc-
tion in the amount of synapsin I upon salt treatment (Fig. 1B and
D). These data suggest that LRRK2 forms a complex with SV.
Next, we investigated if LRRK2 associates to SV through spe-
cific protein-protein interactions. The immunoprecipitation of
LRRK2 showed that well-described SV proteins such as NSF, syn-
taxin 1A, synapsin I, dynamin-1, MUNC18-1, and VAMP2 as well
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as actin and tubulin are LRRK2-interacting proteins (Fig. 1E) (13,
39). LRRK2 contains two domains that typically mediate protein-
protein interactions, an N-terminal LRR and a C-terminal WD40
domain (5, 10, 37). Thus, we proceeded with a systematic analysis
of protein-protein interactions conferred by LRRK2 LRR and
WD40 domains. To this aim, we expressed the LRRK2 LRR and
WD40 domains as GST fusion proteins (herein termed LRRK2
LRR and LRRK2 WD40) (see Fig. S1A in the supplemental mate-
rial). GST-only served as a control in order to detect false positives
caused by unspecific binding to the affinity tag or matrix. Equal
amounts of each protein (baits and control) were loaded onto
glutathione-Sepharose resin and incubated with adult mouse
brain lysates. Interacting proteins were identified by silver staining
(see Fig. S1B), Western blot assays (see Fig. S1C), and MS/MS
spectrometry (see Table S1 in the supplemental material). This
combined approach revealed a panel of 17 and 42 putative inter-
actors for LRRK2 LRR and LRRK2 WD40, respectively, and sug-
gested the C-terminal WD40 domain as an important hub for
protein-protein interaction within LRRK2. Thus, we performed a
more detailed investigation of the interactions conferred by
LRRK2 WD40 combining Western blot assays and MS/MS spec-
trometry. As a protein source, we used mouse brain lysate or the
LS1 fraction, partially enriched in SV. Our analysis identified 84
putative LRRK2 WD40 interactors (Table 1); in particular, we
demonstrated that LRRK2 WD40 has affinity for NSF, syntaxin
1A, synapsin I, VAMP2, Rab3A, MAP2, Rac1, actin, tubulin, and
Hsp90 but not for synaptophysin (Fig. 2). Surprisingly, we found
that LRRK2 WD40 binds endogenous LRRK2, implying a role for
this domain in LRRK2 dimerization (10). WD40 repeats com-
monly constitute a molecular platform for protein-protein inter-
FIG 1 LRRK2 binds presynaptic proteins. (A) Distribution of LRRK2, synapsin I, and synaptophysin immunoreactivities in subcellular fractions of rat forebrain.
LRRK2 is present in highly purified vesicle fractions (US), and its association with the vesicle membrane is not affected by salt treatment (SSV). H, homogenate.
(B) LRRK2 binds to SV. Full-length FLAG-LRRK2, purified from transfected HEK293T cells, was incubated with unstripped SV (US) or salt-stripped SV (SSV)
before high-speed sedimentation. Representative Western blots stained with anti-FLAG antibody show the initial amount of FLAG-LRRK2 protein (total), the
yield of protein precipitated by US or SSV (bound), and the amount of endogenous synapsin I associated to SV. Fusion proteins were incubated with equal
amounts of SV (monitored by antisynaptophysin staining). (C) The graph reports the yield of FLAG-LRRK2 precipitated by US and SSV, expressed as a fraction
of FLAG-LRRK2 total protein and normalized against the SV total protein amount. (D) The graph reports the amount of endogenous synapsin I associated to US
or SSV. Data are expressed as optical density (OD) in arbitrary units. *, P 0.05, n 4 (Student’s t test). (E) Immunoprecipitation of endogenous LRRK2 from
adult brain lysate confirms the interaction between LRRK2 and selected presynaptic and cytoskeletal proteins.
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TABLE 1 Identification of LRRK2 WD40 interactors







P60711 (P60710) Actin, beta Actb MS, WB, IP 42 46.0 17 LS1, total brain
P85515 Alpha-centractin Actr1a MS, WB 43 16.0 4 LS1 fraction
P39069 Adenylate kinase 1 Ak1 MS 22 14.0 2 LS1 fraction
Q9DBG3 Adaptor-related protein complex 2, beta 1 subunit Ap2b1 MS 105 4.0 4 Total brain
Q08163 Adenylyl cyclase-associated protein 1 Cap1 MS 52 6.0 2 LS1 fraction
P84079 ADP-ribosylation factor 1 Arf1 MS 21 15.0 2 LS1 fraction
Q5XI73 Rho GDP dissociation inhibitor (GDI) alpha Arhgdia MS 23 33.0 4 LS1 fraction
Q8VDN2 ATPase, Na	/K	 transporting, alpha 1 polypeptide Atp1a1 MS 113 17.0 4 Total brain
Q6PIE5 ATPase, Na	/K	 transporting, alpha 2 polypeptide Atp1a2 MS 112 17.0 5 Total brain
P06687 ATPase, Na	/K	 transporting, alpha 3 polypeptide Atp1a3 MS 112 12.0 10 LS1 fraction
Q9R0K7 ATPase, Ca2	 transporting, plasma membrane 2 Atp2b2 MS 133 4.0 3 Total brain
Q03265 ATP synthase alpha subunit, isoform 1 Atp5a1 MS 60 21.0 12 LS1 fraction
P56480 (P10719) ATP synthase beta subunit Atp5b MS 56 13.0 5 LS1 fraction, total
brain
P62815 V-type proton ATPase subunit B, brain isoform Atp6v1b2 MS 57 36.0 14 LS1 fraction
Q6PCU2 ATPase, H	 transporting, lysosomal V1 subunit E1 Atp6v1e1 MS 26 15.0 4 LS1 fraction
P47728 Calbindin 2 Calb2 MS 31 14.0 3 LS1 fraction
P28480 T-complex protein 1 subunit alpha Tcp1 MS 60 11.0 5 LS1 fraction
Q5XIM9 T-complex protein 1 subunit beta Cct2 MS 57 18.0 6 LS1 fraction
Q68FD5 Clathrin, heavy polypeptide (Hc) Cltc MS 192 24.0 28 Total brain
P63041 Complexin 1 Cplx1 MS 15 17.0 2 LS1 fraction
P39053 Dynamin 1 Dnm1 MS, IP 98 8.0 7 Total brain
Q62952 Dihydropyrimidinase-like 3 Dpysl3 MS 62 31.0 7 LS1 fraction
P38650 Dynein cytoplasmic 1 heavy chain 1 Dync1h1 MS 532 18.0 4 LS1 fraction
P85845 Fascin homolog Fscn1 MS 54 9.0 3 LS1 fraction
P50398 Rab GDP dissociation inhibitor alpha Gdi1 MS 51 49.0 16 LS1 fraction
P50399 Rab GDP dissociation inhibitor beta Gdi2 MS 51 25.0 5 LS1 fraction
P59215 (P18872) Guanine nucleotide-binding protein G(o) subunit
alpha
Gnao1 MS 40 12.0 3 LS1 fraction, total
brain
P07901 Heat shock protein 90, alpha Hsp90aa1 MS, WB 85 5.0 2 Total brain
P11499 Heat shock protein 90, beta Hsp90ab1 MS, WB 83 7.0 2 Total brain
O35814 Stress-induced phosphoprotein 1 Stip1 MS 63 10.0 4 LS1 fraction
Q2PQA9 Kinesin-1 heavy chain Kif5b MS 110 4.0 3 LS1 fraction
Q9WV63 Kinesin-like protein KIF2A Kif2a MS 80 5.0 3 LS1 fraction
P63086 Mitogen-activated protein kinase 1 Mapk1 MS 41 20.0 6 LS1 fraction
Q3B8Q0 Microtubule-associated protein RP/EB family
member 2
Mapre2 MS 37 11.0 2 LS1 fraction
P19332 Microtubule-associated protein tau Mapt MS 76 7.0 5 LS1 fraction
P34926 Microtubule-associated protein 1A Map1a MS 300 2.0 3 LS1 fraction
P15205 Microtubule-associated protein 1B Map1b MS 270 2.0 5 LS1 fraction
P15146 (P20357) Microtubule-associated protein 2 Map2 MS 199 6.0 6 LS1 fraction, total
brain
Q9QYF3 Myosin VA Myo5a MS 212 5.0 8 LS1 fraction
Q63610 Tropomyosin alpha-3 Tpm3 MS 29 19.0 4 LS1 fraction
P85969 Beta-soluble NSF attachment protein Napb MS 34 11.0 3 LS1 fraction
Q9Z0E0 Neurochondrin Ncdn MS 79 4.0 2 LS1 fraction
P46460 N-Ethylmaleimide sensitive fusion protein Nsf MS, WB, IP 83 10.0 6 Total brain
Q9QXU9 ProSAAS Pcsk1n MS 27 18.0 5 LS1 fraction
Q9EPC6 Profilin 2 Pfn2 MS 15 18.0 3 LS1 fraction
P60203 Proteolipid protein (myelin) 1 Plp1 MS 30 9.0 2 LS1 fraction
P63329 PP2B catalytic subunit alpha isoform Ppp3ca MS 59 28.0 11 LS1 fraction
Q63716 Peroxiredoxin 1 Prdx1 MS 22 20.0 3 LS1 fraction
P35704 Peroxiredoxin 2 Prdx2 MS 22 31.0 8 LS1 fraction
O35244 Similar to peroxiredoxin 6 Prdx6 MS 25 32.0 5 LS1 fraction
P63011 Ras-related protein Rab-3A Rab3a WB 25 31.0 7 Total brain
Q9WU34 Neuron-specific septin-3 Sept3 MS 41 11.0 4 LS1 fraction
Q9JJM9 Septin 5 Sept5 MS 43 10.0 3 LS1 fraction
Q9WVC0 Septin 7 Sept7 MS 51 15.0 5 LS1 fraction
O35179 Endophilin-A1 Sh3gl2 MS 40 29.0 9 LS1 fraction
Q5PPJ9 Endophilin-B2 Sh3glb2 MS 45 8.0 3 LS1 fraction
(Continued on following page)
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actions (12). In order to determine the specificity/exclusiveness of
the protein interactions determined by LRRK2 WD40, we inves-
tigated the interactome of RACK1, an unrelated protein encom-
passing a well-defined WD40 repeat domain (40). We performed
pulldown experiments using full-length RACK1 fused to GST as a
bait protein and analyzed the coprecipitated proteins by Western
blotting (see Fig. S2A and B in the supplemental material) and
mass spectrometry (see Table S2). As a result of this analysis, we
found that only seven putative LRRK2 WD40 binding partners
demonstrated affinity also for RACK1. Notably, among them, we
did not identify LRRK2 itself, MAP2, actin, syntaxin 1A, and NSF,
indicating that these proteins are bona fide specific binders of
LRRK2 WD40.
For further analysis, we elaborated the interactome conferred
to LRRK2 by its WD40 domain, in silico, using the STRING pro-
tein database tools (accessible online at http://string-db.org) (41).
The resulting scale-free network was visualized by Cytoscape soft-
ware (42). The network included 85 nodes (84 interactors plus
LRRK2) connected by 160 edges (see Fig. S3 and Table S3 in the
supplemental material). In order to identify major hubs within the
network, the complete data set was filtered for those nodes quali-
fied by a degree of connectivity higher than four. The filtered data
set formed a subnetwork of 21 nodes associated through 62 edges
(Fig. 3A). Interestingly, proteins represented in this subnetwork
are key determinants of SV trafficking (Fig. 3B). Taken together,
our data suggest that the C-terminal WD40 domain of LRRK2
serves as a major hub for its interaction with other proteins and
that LRRK2 is part of a highly interconnected protein network
involved in synaptic vesicle trafficking.
The LRRK2 WD40 domain induces neurotoxicity. It has been
reported that the C-terminal LRRK2 WD40 domain is required
for LRRK2-associated neurotoxicity (10). To gain a better under-
standing of this phenomenon, we cotransfected cortical neurons
at DIV3 with GFP and vectors expressing either DsRed, the iso-
lated LRRK2 WD40 domain (RFP-LRRK2 WD40), truncated
LRRK2 lacking the C-terminal domain (RFP LRRK2 1–2141),
full-length LRRK2 (RFP-LRRK2), or full-length RACK1 (RFP-
RACK1) and analyzed neuron morphology at DIV16 (Fig. 4). The
overexpression of the full-length RFP LRRK2 severely reduced the
number of processes compared to control neurons expressing
DsRed. This outcome might be related to the high expression of
recombinant full-length LRRK2 achieved in our model (43). In-
terestingly, while ectopic LRRK2 1–2141 expression did not sig-
nificantly alter neuron morphology, overexpression of the single
TABLE 1 (Continued)







P60881 Synaptosome-associated protein 25 Snap25 MS, WB 23 14.0 2 LS1 fraction
Q61548 Synaptosome-associated protein 91 Snap91 MS 92 4.0 3 Total brain
P37377 Synuclein, alpha Snca MS 14 39.0 3 LS1 fraction
Q91ZZ3 Synuclein, beta Sncb MS 14 50.0 5 LS1 fraction
P16546 Spectrin alpha 2 Spna2 MS 285 4.0 9 Total brain
Q62261 Spectrin beta 2 Spnb2 MS 274 1.0 2 Total brain
P63039 60-kDa heat shock protein Hspd1 MS 61 46.0 25 LS1 fraction
O35814 Stress-induced phosphoprotein 1 Stip1 MS 63 10.0 4 LS1 fraction
P13668 Stathmin Stmn1 MS 17 36.0 5 LS1 fraction
P61264 Syntaxin 1B Stx1b MS 33 13.0 3 Total brain
P61765
(O08599)
Syntaxin-binding protein 1 Stxbp1 MS, IP 68 19.0 10 LS1 fraction, total
brain
Q9JIS5 Synaptic vesicle glycoprotein 2A Sv2a MS 83 5.0 2 Total brain
O88935 Synapsin-1 Syn1 WB, IP 75 16.0 5 Total brain
Q63537
(Q64332)
Synapsin-2 Syn2 WB, IP 63 17.0 7 LS1 fraction, total
brain
Q62910 Synaptojanin 1 Synj1 MS 173 4.0 5 LS1 fraction
Q6P9V9
(Q99KA2)
Tubulin alpha-1B chain Tuba1b MS, WB, IP 50 45.0 21 LS1 fraction, total
brain
Q5XIF6 Tubulin alpha-4A chain Tuba4a MS 50 36.0 5 LS1 fraction
P85108 Tubulin beta-2A chain Tubb2a MS 50 64.0 2 LS1 fraction
Q3KRE8 Tubulin beta-2B chain Tubb2b MS 50 64.0 10 LS1 fraction
Q4QRB4 Tubulin beta-3 chain Tubb3b MS 50 66.0 12 LS1 fraction
Q6P9T8 Tubulin beta-4B chain Tubb4b MS 50 63.0 28 LS1 fraction
P69897 Tubulin beta-5 chain Tubb5b MS 50 63.0 6 LS1 fraction
Q00981 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Uchl1 MS 25 37.0 6 LS1 fraction
P63045 Vesicle-associated membrane protein 2 Vamp2 MS, WB, IP 13 46.0 6 LS1 fraction
P35213 14-3-3 protein beta polypeptide Ywhab MS 28 30.0 2 LS1 fraction
P62259 14-3-3 protein epsilon polypeptide Ywhae MS 29 16.0 2 Total brain
P68511 14-3-3 protein eta polypeptide Ywhah MS 28 52.0 7 LS1 fraction
P68255 14-3-3 protein theta Ywhaq MS 28 30.0 4 LS1 fraction
a UniProtKB/Swiss-Prot accession numbers.
b Interactors were found by immunoprecipitation of endogenous LRRK2 (IP) or LRRK2 WD40 pulldown assays analyzed by Western blotting (WB) and mass spectrometry (MS).
c Sequence coverage for proteins identified by LC-MS/MS.
d Number of identified unique peptides.
e Lysate from adult mouse brain (total brain) or the LS1 fraction.
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LRRK2 WD40 domain significantly impaired process number.
Given the severe neurotoxicity observed upon expression of RFP
WD40 and RFP LRRK2 from DIV3 to DIV16, we modified our
experimental setup and investigated the effect of ectopic LRRK2
construct expression in neurons transfected at DIV10 and imaged
at DIV16 (Fig. 5A). Given that we experienced an extremely low
efficiency when transfecting full-length LRRK2 in primary cul-
tures at DIV10 (data not shown), we excluded this condition in
subsequent experiments. While ectopic DsRed, RACK1, and
LRRK2 1–2141 were diffusely distributed in neuronal soma and
along neuronal processes, partially colocalizing with the synaptic
marker SNAP-25, we found that the ectopically expressed LRRK2
WD40 domain was mainly localized in a perinuclear somatic re-
gion, with low colocalization with SNAP-25 (see Fig. S4 in the
supplemental material). Next, we considered neuron morphol-
ogy. The overexpression of RFP-LRRK2 WD40 significantly re-
duced the number of processes and increased the amount of swol-
len or fragmented neurites compared to control neurons. In
contrast, ectopic LRRK2 1–2141 expression did not influence total
neurite number and was associated to a milder increase of swollen
processes than LRRK2 WD40. Finally, we found an increased
number of processes in RACK1-overexpressing neurons (Fig. 5B
and C). Given that neuronal fragmentation represents the first
sign of neuronal sufferance (44), our data indicate that the pro-
longed expression of the isolated LRRK2 WD40 domain induces
toxicity in neurons.
LRRK2 WD40 domain and RACK1 alter SV trafficking.
Given the interactions described between the LRRK2 WD40 do-
main and presynaptic proteins, we wondered whether the LRRK2
WD40 domain affects proper SV trafficking and distribution. To
test this hypothesis, we cotransfected cortical neurons at DIV10
with GFP and either DsRed, RFP-LRRK2 WD40, RFP-RACK1, or
LRRK2 1–2141 expression vectors. At DIV12 we determined the
SV exoendocytic rate by exposing living cortical neurons to an
antisynaptotagmin antibody as previously described (13). Trans-
fected neurons were then tracked via laser confocal microscopy.
Recycling vesicles appeared as synaptotagmin-positive clusters
along GFP-positive neuronal processes (Fig. 6A). The total vesicle
pool was estimated by staining with antibodies directed against an
integral SV protein (SV2A) after fixation and permeabilization of
the cells (Fig. 6B). While ectopic LRRK2 1–2141 did not influence
synaptotagmin uptake, the overexpression of RFP-LRRK2 WD40
as well as RFP-RACK1 induced a significant decrease in the num-
ber of synaptotagmin-positive clusters (Fig. 6C). At the same time,
neither LRRK2 WD40 nor RACK1 nor LRRK2 1–2141 overex-
pression affected the amount of SV2A-positive clusters compared
to DsRed transfected neurons (Fig. 6D). Next, we examined if the
expression of LRRK2 WD40, RACK1, or LRRK2 1–2141 had an
impact on the distribution of cycling or total SV pools. To this end,
we tracked the distribution of synaptotagmin (cycling SV) and
SV2A-positive (total SV) clusters along GFP-positive processes.
Interestingly, in LRRK2 WD40 transfected neurons, synaptotag-
min-positive clusters were mainly distributed proximally to the
cellular soma while SV2A-positive clusters were homogeneously
diffused along the entire length of the neurites (Fig. 6E and F).
Taken together, these data strongly indicate that ectopic expres-
sion of the LRRK2 WD40 domain influences trafficking, distribu-
tion, and topology of the SV cycling pool.
FIG 2 The C-terminal WD40 domain of LRRK2 represents a hub for protein-protein interactions. Western blots are shown, confirming the specific interaction
of proteins following a domain-based pulldown assay for the LRRK2 WD40 domain. s-physin, synaptophysin.
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The G2385R PD risk variant alters LRRK2 WD40 binding
properties to synaptic vesicles. The critical role conferred by the
LRRK2 WD40 domain is suggested by the existence of the G2385R
polymorphism, described as a risk factor for the development of
PD (14–16).
Sequence alignments and secondary structure predictions sug-
gest that the LRRK2 C terminus contains a WD40 propeller do-
main composed of seven -blades. We assessed the structure of
the region comprising LRRK2 residues 2124 to 2499 using homol-
ogy modeling in order to gain information about the structural
features of the LRRK2 C terminus (Fig. 7A; see also Fig. S5A in the
supplemental material). Our model, based on the structure of the
WD40 protein RACK1 from Arabidopsis thaliana (34), shows that
the LRRK2 C-terminal domain is compatible with the character-
istic structure of WD40 domains, i.e., seven -propeller repeats
combined to a cleft of basic residues (5, 15). A more detailed
analysis of the region surrounding the residue G2385 revealed that
G2385 lies in close vicinity of two hydrophobic residues, V2375
FIG 3 LRRK2 interacts with presynaptic proteins. (A) The network of LRRK2 interactors was modeled from STRING annotation on the Cytoscape represen-
tation. annotated, interactions annotated on STRING; experimental, interactions described in the manuscript. (B) Gene symbols, names, and gene ontology
(GO) terms for the proteins included in the network.
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and L2439, on one side and with R2442 and R2443 on the other
side. Even with its limitations, the structural model suggests that
the substitution of G2385 with a bulky and positively charged
arginine residue would lead to unfavorable charge repulsions and
potentially conformational changes of the protein near the inter-
face between -blades 5 and 6. This might not only alter the local
conformation but also affect the binding surface of WD40 for
interaction with interacting proteins and thus impair LRRK2 ac-
tivity. In order to experimentally assess the structural properties of
the LRRK2 C terminus and the alterations caused by the G2385R
variant, purified GST fusion proteins LRRK2 WD40 and LRRK2
WD40 G2385R were analyzed by transmission electron micros-
copy (EM). To meet the demand of EM for highly pure material,
purity and concentration of the GST fusion proteins were con-
firmed by SDS-PAGE (see Fig. S2A in the supplemental material).
While particles with distinct shapes were discernible on electron
micrographs of negatively stained LRRK2 WD40 fusion proteins,
similar structures were not visible for the GST tag alone (see Fig.
S5B). Single-particle classification and averaging indicated the ex-
istence of particle populations with an annular, doughnut-like
appearance and diameters ranging from 5 to 8 nm for LRRK2
WD40 (Fig. 7B). Structures similar in size and shape were also
detected for the GST-RACK1 fusion protein (Fig. 7B), indicating
that the fold of the LRRK2 WD40 domain is comparable despite
limited sequence homology. To ensure that the fusion of the
WD40 domains to the GST tag does not induce ring-like struc-
tures, N-terminal 6His-tagged LRRK2 WD40 was subjected to
EM (see Fig. S5C in the supplemental material). Although the
FIG 4 Expression of an LRRK2 WD40 domain construct is sufficient to induce neurotoxicity in primary neurons. Neurons were transfected at DIV3 and
imaged at DIV16. Long-lasting overexpression of RFP-LRRK2 WD40 and full-length RFP-LRRK2 significantly reduced the number of processes and
increased the amount of swollen or fragmented neurites compared to levels in DsRed-, RFP LRRK2 1–2141-, or RFP-RACK1-transfected neurons. Images
show signals acquired for GFP (channel 1, CH1), DsRed or RFP (channel 2, CH2), superimposed channel signals (merge), and tracings. Arrow heads
indicate an RFP-LRRK2 WD40-positive cell. Numbers in the tracing panel indicate total process numbers and are expressed as means SE. **, P 0.01
versus DsRed; #, P 0.01 versus full-length RFP-LRRK2 (ANOVA; Tukey’s post hoc test, n 3; 8 neurons were analyzed for each experimental case). Panel
size shown is 200 by 200 m.
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protein lacking the GST tag turned out to be more aggregation
prone, doughnut-like structures similar in size and appearance to
those observed in GST fusion proteins were still present. The anal-
ysis of the LRRK2 WD40 G2385R variant by EM revealed strong
similarity to the other WD40 domain constructs, however, with a
wider size distribution ranging from 5 to 13 nm. This larger size
heterogeneity may be due to structural alterations in WD40 in-
duced by electrostatic repulsion in the -propeller fold, as sug-
gested by the structural model.
In order to further characterize the G2385R variant, we inves-
tigated the impact of LRRK2 WD40 G2385R overexpression on
neurons. Ectopic LRRK2 WD40 G2385R induced neuronal toxic-
ity and sequestered cycling SV to a similar extent as LRRK2 WD40
(see Fig. S6 in the supplemental material).
The data presented above suggest that the WD40 domain
plays a major role in tethering LRRK2 to SV via protein inter-
actions; thus, we asked if the G2385R variant can influence
LRRK2 binding to SV. To explore this hypothesis, we incubated
FIG 5 Expression of an LRRK2 WD40 domain construct induces neurotoxicity in primary neurons. (A) Neurons were transfected at DIV10 and imaged at
DIV16. Long-lasting overexpression of RFP-LRRK2 WD40 significantly reduced the number of processes and increased the amount of swollen or fragmented
neurites compared to levels in DsRed-, LRRK2 1–2141-, or RFP-RACK1-transfected neurons. Images show signals acquired for GFP (channel 1, CH1), DsRed
or RFP (channel 2, CH2), superimposed channel signals (merge), and tracings. Graphs report the number of total processes (B) and number of fragmented
processes (C) (means SE). *, P 0.05 versus DsRed; **, P 0.01 versus DsRed; #, P 0.05 versus LRRK2 WD40 (ANOVA; Tukey’s post hoc test, n 4; 7
neurons were analyzed for each experimental case). Panel size shown is 200 by 200 m.
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LRRK2 WD40 and LRRK2 WD40 G2385R as well as RACK1
GST fusion proteins at nanomolar concentrations with puri-
fied SV and tested the extent of binding by the means of a
high-speed sedimentation assay (24). Western blot analysis us-
ing a GST-specific antibody revealed that LRRK2 WD40 as well
as LRRK2 WD40 G2385R and RACK1 binds to purified SV
(Fig. 7C to E) while GST alone failed to bind SV at significant
rates (see Fig. S5D in the supplemental material). As mild salt
treatment partially washes away peripheral SV proteins, we ex-
ploited this feature to further investigate the binding properties
FIG 6 The LRRK2 WD40 domain sequesters cycling synaptic vesicles. The exoendocytotic assay was performed at DIV12 on cortical neurons transfected at DIV10. (A)
Cycling SV appear as synaptotagmin (s-tagmin)-positive clusters along neuron processes. Images show signals acquired for synaptotagmin (channel 1, CH1) and DsRed
or RFP or FLAG (channel 2, CH2) and their superimposition plus GFP (merge). (B) The total SV pool was revealed by staining with anti-SV2A antibodies upon
permeabilization. Images show signals acquired for SV2A (channel 1, CH1) and DsRed or RFP (channel 2, CH2) and their superimposition plus GFP (merge). (C) SV
cycling is strongly reduced upon either LRRK2 WD40 or RACK1 overexpression. The graph reports the number of synaptotagmin-positive clusters per 10 m of
GFP-positive process. (D) The total number of SV pools was not altered by LRRK2 WD40, RACK1, or LRRK2 1–2141 overexpression. (E and F) Ectopically expressed
LRRK2 WD40 confines cycling SV within a perisomatic region, while total SV pool distribution is not affected. The graph reports the percentage of synaptotagmin- or
SV2A-positive clusters distributed within the proximal half of the process. Data are expressed as means SE. *, P 0.01 versus DsRed (ANOVA; Tukey’s post hoc test,
n 4; 7 neurons were analyzed for each experimental case). Panel length is 10m.
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of the three fusion proteins. Interestingly, the salt treatment
did not alter the SV association of LRRK2 WD40 and RACK1,
whereas the affinity/binding strength of the LRRK2 WD40
G2385R domain to salt-treated SV was significantly reduced
(Fig. 7C to E).
Taken together, these results suggest that the structural altera-
tion induced by the G2385R substitution functionally disturbs
LRRK2 WD40 binding properties to SV.
DISCUSSION
Since the first description of LRRK2 as a PD-causative gene, major
attention has been devoted to its GTPase and kinase activity,
linking disease-associated mutations to altered functional and
(patho)physiological enzymatic properties of the protein (45–50).
However, LRRK2 C-terminal deletion mutants fail to induce
apoptosis and toxicity and demonstrate a reduced kinase activity
(Fig. 4 and 5) (10, 51). These reports, however, do not address the
question of whether the kinase domain or WD40 domain or both
are causative for PD pathology. We, on the other hand, observed
that the severe toxicity induced by overexpression of full-length
LRRK2 in primary cultures is mimicked by ectopic expression of a
construct containing only the C-terminal WD40 domain of
LRRK2. Noticeably, in contrast to LRRK2 WD40, RACK1, an-
other WD40 protein, has a positive effect on neurite complexity.
These data suggest that the C-terminal WD40 domain has a major
role in LRRK2-associated toxicity (43).
FIG 7 The G2385R substitution impacts the local structure of LRRK2 WD40. (A) Combined stick-and-ribbon representation showing a structural
homology model (based on RACK1 from Arabidopsis thaliana, PDB 3DM0) for the LRRK2 WD40 domain. The N terminus, C terminus, and the position of
G2385 (red sphere) are indicated. (B) Transmission EM images of negatively stained (1% uranyl acetate) LRRK2 WD40, LRRK2 WD40 G2385R, and RACK1
proteins show doughnut-shaped particles consistent with the characteristic structure of WD40 folds. Four representative averaged single-particle two-dimen-
sional projections are shown for each protein (scale bar, 5 nm). (C) LRRK2 WD40 binds SV. Increasing nanomolar amounts of LRRK2 WD40, LRRK2 WD40
G2385R domains, and RACK1 protein were incubated with unstripped SV (US) or salt-stripped SV (SSV) before high-speed sedimentation. Representative
Western blots show initial amount of fusion protein (total) and the yield of GST fusion proteins precipitated by US or SSV (bound). Fusion proteins were
incubated with equal amounts of SV (monitored by antisynaptophysin staining). (D) The table reports the dissociation constant (KD) describing the binding
between the indicated fusion protein and US or SSV. Data are expressed as means SE. *,P 0.05 versus LRRK2 WD40 G2385R binding to US; °,P 0.01 versus
LRRK2 WD40 binding to SSV (ANOVA; Tukey’s post hoc test, n 4). (E) The graph reports the yield of precipitated GST fusion protein normalized versus the
SV total protein amount (average data plus fitting) on the y axis and the initial amount of GST fusion protein on the x axis.
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From structural prediction it appears likely that the LRRK2
WD40 domain folds as a seven-bladed propeller (15, 52). How-
ever, sequence homology is considerably low, and no experimen-
tal evidence for this assumption has existed so far. According to
our EM analysis, the purified LRRK2 WD40 fusion protein forms
doughnut-like structures with an average diameter of 5 to 8 nm,
resembling EM structures reported for known WD40-containing
proteins such as the splicing factor Prp19p (53) or RACK1 (this
paper). These findings suggest that the LRRK2 C terminus may
indeed form a propeller-like structure, in agreement with a WD40
fold. WD repeat-containing proteins execute a broad spectrum of
critical functions. They participate in organizing cytoskeleton as-
sembly, mitotic spindle formation, and vesicular trafficking (11,
12, 54, 55). Furthermore, increasing evidence describes WD40
repeat domains as molecular hubs orchestrating complex protein-
protein interactions. Structurally, this feature is based on the evo-
lutionary principle to generate binding epitopes with different
specificities by concatenation of stable folded repeats and loops
with variable sequences (11). Following the “guilt by association”
principle (56), we systematically analyzed the domain-specific in-
teractome of the LRRK2 C terminus in order to assign specific
physiological functions to this domain. Through its WD40 do-
main, LRRK2 interacts with critical players of the SV cycle such as
NSF, syntaxin 1A, synapsin I, dynamin-1, MUNC18-1, VAMP2,
synaptojanin, and synuclein. Thus, the ability of LRRK2 to influ-
ence vesicle trafficking (13, 37, 38) is likely to involve its WD40
domain. Accordingly, we observed a severe reduction in the trans-
port of synaptotagmin-labeled (cycling) SV to distal parts of neu-
ronal processes upon overexpression of LRRK2 WD40 domain
constructs; such output might be read as a dominant negative
effect of ectopic LRRK2 WD40 executed on endogenous LRRK2
function. RACK1 is a seven-bladed WD40 propeller protein (19,
40), reported to bind and anchor recycling endosomal vesicles to
centrosomes (57). Accordingly, we reported that RACK1 signifi-
cantly reduces SV recycling (but not spatial segregation) once it is
overexpressed in neurons and that it cosediments with pure SV.
Thus, the ability to bind and sequester SV might be a biochemical
property common to several WD40-containing proteins or, alter-
natively, might arise as an in vitro effect due to high local concen-
trations of WD40 domains. Even if we cannot completely rule out
the latter explanation, our data suggest a peculiar physiological
role for LRRK2 at the synaptic site. In fact, we demonstrated here
that endogenous LRRK2 can be detected in a pure SV fraction,
that full-length LRRK2 binds SV, and that LRRK2 WD40, but not
LRRK2 LRR or full-length RACK1, interacts with several proteins
involved in SV trafficking. Thus, we propose that LRRK2 associa-
tion with SV is mediated by the interaction of its WD40 domain
with SV-integral and -associated proteins.
The description of the G2385R point mutation within the
WD40 domain as the main PD risk variant in the Chinese Han and
Korean population further underlines the functional and patho-
logical role of this domain (14). G2385R carrier patients demon-
strate clinical features similar to noncarrier patients; however, the
G2385R variant does correlate to a small but significant effect in
lowering the age of PD onset (16). It has recently been reported
that G2385R has a mild impact on LRRK2 biochemical properties,
such as reduced LRRK2 kinase activity and interactions with other
proteins (9), while it neither influences LRRK2 toxicity in neuron
cultures nor affects overall autophosphorylation (46). Accord-
ingly, we reported here that LRRK2 WD40 G2385R behaved sim-
ilarly to LRRK2 WD40 once it was overexpressed in primary neu-
rons. Comparative protein models predict that the glycine 2385
residue stays at the surface of the WD40 domain (Fig. 7A) (15).
The G2385R variant replaces the glycine with a long, positively
charged arginine residue, thus increasing the net positive charge of
the domain and likely inducing an electrostatic repulsion between
WD40 repeats 5 and 6. This may explain the increased mean di-
ameter observed for LRRK2 WD40 G2385R in our EM analysis.
The changes in surface charge and local structural features in the
WD40 fold are expected to result in altered biochemical properties
which affect protein-protein interaction strength and quality. In-
deed, we reported that the association with SV is partially im-
paired by the glycine-to-arginine change. In particular, while
LRRK2 WD40 showed a high affinity toward both native and salt-
treated SV, LRRK2 WD40 G2385R binding to SV was significantly
sensitive to salt treatment. In line with our proposal of LRRK2 as a
synaptic scaffold protein involved in vesicular trafficking and ves-
icle storage, our data strongly support the idea that in addition to
increased kinase activity, other molecular mechanisms, such as
altered protein binding, may underlie LRRK2-associated forms of
PD. In particular, given the recent independent evidence linking
LRRK2 dysfunction to neurotransmission defects in PD models
(58–60) and in patients carrying LRRK2 mutations (61), an al-
tered presynaptic vesicle transport, storage, and release kinetics
may arise as a common pathway disturbed by the different LRRK2
pathological mutations described so far and become a future tar-
get for pharmacological treatment.
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